A Targeted Therapy Next in Line for Biomarker-based Cancer Drug Approval?

recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib (LOXO-101), which showed promising results in adults and children with a variety of cancer types, all of which had one thing in common – fusions involving the gene TRK.

Read More

Catching Childhood Cancers Early: Insights Into the AACR Childhood Cancer Predisposition Workshop

There is perhaps nothing more painful for parents than receiving a cancer diagnosis for their child. Childhood cancers are generally rare, and in the United States, the death rates have …

Read More

Heading Into Summer, Please “Don’t Fry”

Today is National “Don’t Fry Day,” an initiative undertaken by the National Council on Skin Cancer Prevention to encourage sun safety awareness and to remind people to limit their exposure to ultraviolet (UV) radiation, which has been proven to cause skin cancer.

Read More

Do Genomic Approaches to Selecting Cancer Treatment Yield Better Patient Outcomes Than Traditional Approaches?

A study published recently in the AACR’s journal Cancer Discovery addresses the burgeoning question of the utility of high-throughput genomic analysis in identifying targeted therapies and delivering better outcomes for cancer patients, and adds important evidence to argue in favor of such an approach. The jury, nevertheless, is still out.

Read More

Improving Cancer Surgery: Using a Probe to Determine What is Cancer, What is Not

A team of researchers from Australia has shown that an optical fiber-tip probe that can detect the pH of a tissue can distinguish between cancer and normal tissues at the margins of a tumor during surgery, in real time.

Read More

One More Reason to Stay Trim: Reduce Your Liver Cancer Risk

Liver cancer rates have been on the rise in the United States and have tripled in the last four decades. A study published in 2014 in the AACR’s journal Cancer Research projected that pancreatic cancer and liver cancer will surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer death, following lung cancer.

Read More